228 related articles for article (PubMed ID: 27131284)
21. Dabigatran: its protective effect against endothelial cell damage by oxysterol.
Gorzelak-Pabiś P; Broncel M; Pawlos A; Wojdan K; Gajewski A; Chałubiński M; Woźniak E
Biomed Pharmacother; 2022 Mar; 147():112679. PubMed ID: 35121342
[TBL] [Abstract][Full Text] [Related]
22. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.
Chen B; Soto AG; Coronel LJ; Goss A; van Ryn J; Trejo J
Mol Pharmacol; 2015 Jul; 88(1):95-105. PubMed ID: 25934730
[TBL] [Abstract][Full Text] [Related]
23. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity.
Dólleman SC; Agten SM; Spronk HMH; Hackeng TM; Bos MHA; Versteeg HH; van Zonneveld AJ; de Boer HC
J Thromb Haemost; 2022 Apr; 20(4):996-1007. PubMed ID: 35037739
[TBL] [Abstract][Full Text] [Related]
24. Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.
Altieri P; Bertolotto M; Fabbi P; Sportelli E; Balbi M; Santini F; Brunelli C; Canepa M; Montecucco F; Ameri P
Int J Cardiol; 2018 Nov; 271():219-227. PubMed ID: 29801760
[TBL] [Abstract][Full Text] [Related]
25. Testing for dabigatran and rivaroxaban by clinical laboratories.
Van Cott EM; Smock KJ; Chen D; Hsu P; Zantek ND; Meijer P
Am J Hematol; 2016 Nov; 91(11):E464-E467. PubMed ID: 27458812
[TBL] [Abstract][Full Text] [Related]
26. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Werth S; Breslin T; NiAinle F; Beyer-Westendorf J
Am J Cardiovasc Drugs; 2015 Aug; 15(4):235-42. PubMed ID: 25940651
[TBL] [Abstract][Full Text] [Related]
27. Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Vittal Rao H; Bihaqi SW; Iannucci J; Sen A; Grammas P
J Alzheimers Dis; 2021; 79(1):211-224. PubMed ID: 33252072
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Neira V; Corbalán R; Pereira J; Panes O; Garayar B; Aizman A; Llevaneras S; Villarroel L
Rev Med Chil; 2016 Sep; 144(9):1103-1111. PubMed ID: 28060970
[TBL] [Abstract][Full Text] [Related]
29. The Protective Effect of Dabigatran and Rivaroxaban on DNA Oxidative Changes in a Model of Vascular Endothelial Damage with Oxidized Cholesterol.
Woźniak E; Broncel M; Bukowska B; Gorzelak-Pabiś P
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32182973
[TBL] [Abstract][Full Text] [Related]
30. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.
Álvarez E; Paradela-Dobarro B; Raposeiras-Roubín S; González-Juanatey JR
Br J Clin Pharmacol; 2018 Feb; 84(2):280-291. PubMed ID: 28940408
[TBL] [Abstract][Full Text] [Related]
31. Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
Oi K; Shimizu M; Natori T; Tsuda K; Yoshida M; Kamada A; Ishigaku Y; Narumi S; Oura K; Maeda T; Terayama Y
Thromb Res; 2021 May; 201():123-130. PubMed ID: 33667955
[TBL] [Abstract][Full Text] [Related]
32. [Influence of NOACs on Thrombin Generation Assay].
Kawasugi K
Rinsho Byori; 2014 Oct; 62(10):965-9. PubMed ID: 27526542
[TBL] [Abstract][Full Text] [Related]
33. Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines - Slowing the vicious circle of coagulation and inflammation.
Paar V; Jirak P; Gruber S; Prodinger C; Cadamuro J; Wernly B; Motloch LJ; Haschke-Becher E; Hoppe UC; Lichtenauer M
Life Sci; 2020 Dec; 262():118474. PubMed ID: 32961229
[TBL] [Abstract][Full Text] [Related]
34. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Nishimoto S; Yagi S; Yamada H; Soeki T; Wakatsuki T; Shimabukuro M; Sata M
Atherosclerosis; 2015 Oct; 242(2):639-46. PubMed ID: 25817329
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease-Activated Receptor Pathway.
Ichikawa H; Shimada M; Narita M; Narita I; Kimura Y; Tanaka M; Osanai T; Okumura K; Tomita H
J Am Heart Assoc; 2019 Apr; 8(8):e012195. PubMed ID: 30957622
[TBL] [Abstract][Full Text] [Related]
36. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Stief TW
Blood Coagul Fibrinolysis; 2012 Oct; 23(7):619-21. PubMed ID: 22821003
[TBL] [Abstract][Full Text] [Related]
37. Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Vianello F; Sambado L; Goss A; Fabris F; Prandoni P
Cancer Med; 2016 Oct; 5(10):2886-2898. PubMed ID: 27600331
[TBL] [Abstract][Full Text] [Related]
38. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression.
Ishibashi Y; Matsui T; Ueda S; Fukami K; Yamagishi S
Cardiovasc Diabetol; 2014 Mar; 13():60. PubMed ID: 24624928
[TBL] [Abstract][Full Text] [Related]
39. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Friebel J; Moritz E; Witkowski M; Jakobs K; Strässler E; Dörner A; Steffens D; Puccini M; Lammel S; Glauben R; Nowak F; Kränkel N; Haghikia A; Moos V; Schutheiss HP; Felix SB; Landmesser U; Rauch BH; Rauch U
Cells; 2021 Dec; 10(12):. PubMed ID: 34944024
[TBL] [Abstract][Full Text] [Related]
40. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Storey RF; Kotha J; Smyth SS; Moliterno DJ; Rorick TL; Moccetti T; Valgimigli M; Dery JP; Cornel JH; Thomas GS; Huber K; Harrington RA; Hord E; Judge HM; Chen E; Strony J; Mahaffey KW; Tricoci P; Becker RC; Jennings LK
Thromb Haemost; 2014 May; 111(5):883-91. PubMed ID: 24402559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
